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Abstract 
Objective:  The objective was to assess involvement of loss of the PRKAR1A gene 
encoding a type 1α regulatory subunit of cAMP-dependent protein kinase A located on 
17q24 in a Carney complex (CNC)-related pituitary adenoma.  
Design:  We investigated aberrations of the PRKAR1A gene in a CNC patient with a 
GH-producing pituitary adenoma, whose family has 3 other members with probable 
CNC. 
Methods:  A gene mutation was identified by a standard DNA sequencing method 
based on PCR.  DNA copy number was measured to evaluate allelic loss on 17q24 by 
quantitative PCR.  The breakpoints of deletion were determined by cloning a 
rearranged region in the deleted allele.   
Results:  A PRKAR1A mutation of c.751_758del8 (p.S251LfsX16) was found in 
genomic DNA obtained from a pituitary adenoma, but not leukocytes from the patient.  
Reduced DNA copy number at loci including the PRKAR1A gene on 17q24 was 
detected in both the tumor and leukocytes, suggesting a deletion at the loci at the 
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germline level.  The deletion size was determined to be approximately 0.5 Mb and this 
large deletion was also found in other 2 family members.  
Conclusion:  This is the first case showing a CNC-related pituitary adenoma with the 
combination of somatic mutation and a large inherited deletion of the PRKAR1A gene.  
Biallelic inactivation of PRKAR1A may be necessary for the development of 
CNC-related pituitary adenoma. 
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Introduction 
   The complex of “spotty-skin pigmentation, myxomas, endocrine overactivity, and 
schwannomas” or Carney complex (CNC) (MIM 160980) is an autosomal dominant 
multiple neoplasia syndrome (1).  CNC is an inherited predisposition to tumors 
associated with primary pigmented nodular adrenocortical disease (PPNAD), GH- 
and/or PRL-producing pituitary adenoma, myxomas of heart or skin, psammomatous 
melanotic schwannoma, and breast ductal adenoma (2). 
   Previous studies have shown inactivating germline mutations in the PRKAR1A gene 
on 17q24, which may function as a tumor-suppressor gene, in patients with CNC (3, 4).  
The encoded protein is a type 1α regulatory subunit of cAMP-dependent protein kinase 
A (PKA).  Inactivating germline mutations of this gene are found in about 70% of 
patients with CNC (2, 5).  Less commonly, the molecular pathogenesis of CNC is a 
variety of genetic changes on 2p16 (6).   
   Salpea et al. have recently reported that 17q24.2-24.3 deletions of varying size 
including the PRKAR1A gene led to haploinsufficiency in 11 CNC patients without 
PRKAR1A mutations (7); however, biallelic inactivation in CNC-related tumors was not 
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shown.  In the present study, we examined the PRKAR1A locus in a Japanese family 
with CNC and found a large germline deletion of the locus and biallelic inactivation of 
PRKAR1A in a pituitary adenoma. 
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Subjects and methods 
Case report 
   The proband was a young woman who presented with pituitary gigantism and 
pigmented spots on the face and lips.  She had been tall during her childhood and 
reached a height of 183.5 cm.  Incidental pituitary adenoma with a diameter of 15 mm 
was demonstrated by magnetic resonance imaging (MRI) upon investigating her head 
injury (Fig. 1A).  She had increased serum levels of GH (11.0 µg/l) and IGF-1 (590 
µg/l), and the GH levels were not suppressed during oral glucose tolerance test.  Serum 
levels of PRL and cortisol were within the normal range.  She had undergone 
successful transnasal endoscopic adenomectomy at Toranomon Hospital, and the 
resected pituitary adenoma showed unusual unique histological feature.  The adenoma 
was composed of extremely enlarged bizzare eosinophilic cells harboring large nuclei 
with prominent nucleoli (Fig. 1B).  Immunohistochemical study revealed that tumor 
cells were positive to an anti-GH antibody (A0570; DAKO, Glostrup, Denmark) and 
negative to an antibody against type 1α regulatory subunit of PKA (#610610; BD 
Biosciences, San Jose, CA, USA) compared to adjacent normal cells (Fig. 1C and 1D).   
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Family history 
   Her family history was remarkable; her mother (II-2 in Fig. 1E) had been operated 
on for a right adrenal tumor due to Cushing’s syndrome at the age of 19 and her 
grandmother (I-2) for a cardiac tumor at the age of 48.  Both mother and grandmother 
had been operated on for breast tumors, at the ages of 52 and 68, respectively.  An 
elder sister (III-1) underwent surgical operations for a gingival tumor at the age of 2 and 
eyelid tumors at the ages of 13 and 16.  One of the eyelid tumors was pathologically 
diagnosed as cutaneous myxoma.  Spotty facial pigmentation was present.   
   This study was approved by the ethics committees of Toranomon Hospital and The 
University of Tokushima.  Individual informed consents for genomic analyses and 
case presentations were obtained from the patients. 
 
Gene mutation analysis 
   Gene mutation analysis for the PRKAR1A gene using polymerase chain reaction 
(PCR) and sequencing was performed as described previously (8).  Genomic DNA 
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isolated from leukocytes and a frozen pituitary adenoma was subjected to PCR using 
TaKaRa Ex TaqTM Polymerase (TaKaRa, Shiga, Japan) with the PRKAR1A primer sets.  
PCR products were subjected to direct sequencing in sense and antisense directions. 
 
DNA copy number analysis in a tumor and leukocytes 
   Relative DNA copy number at each locus on 17q24 was measured by quantitative 
PCR (qPCR) in a 7300 Real Time PCR System (Applied Biosystems, Foster City, CA, 
USA) using THUNDERBIRD SYBR qPCR mix (Toyobo, Osaka, Japan) with each 
primer set shown in supplementary Table.  Specificity of the primer pairs was verified 
by dissociation curves and the quantitativity was confirmed by slopes in the standard 
samples for the target loci being between -3.6 and -3.2 and each R2 value being 
between 0.99 and 1.  The DNA copy number was normalized using that of human 
TATA-binding protein (TBP) located on 6q27.  Furthermore, DNA copy numbers of 
albumin (ALB) on 4q13.3 or telomerase reverse transcriptase (TERT) on 5p15.33 were 
confirmed to be almost equal among the samples. 
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Detection of deleted allele on 17q24 in the subjects 
   DNA encompassing the deletion junction on 17q24 was amplified from each 
subject’s leukocyte genomic DNA by using TaKaRa Ex TaqTM Polymerase with the 
following primers: forward: 5´-GGGACCATCCTGGCTAACACG-3´, reverse: 
5´-GGACATCTGACCTACAAAACTGTGAGC-3´.  Normal female DNA (Promega, 
Madison, WI) and pBluescript II SK+ with a DNA fragment including the deletion 
junction were used as a negative control and a positive control, respectively.  PCR 
using a primer set for the TERT gene as an internal control was also performed.  
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Results 
Somatic mutation and one-copy deletion of the PRKAR1A gene in a pituitary 
adenoma 
   We examined mutations of the PRKAR1A gene in genomic DNA from a pituitary 
adenoma and from leukocytes of a proband (III-2 in Fig. 1E) and her parents (II-1 and 
II-2), using direct sequencing of 11 overlapping PCR products with primer sets that 
cover the entire coding region and splicing junctions.  Sequencing analysis showed no 
mutations in the PRKAR1A gene in leukocyte genomic DNA from all subjects, but a 
somatic mutation of c.751_758del8 (p.S251LfsX16) in exon 8 of the PRKAR1A gene in 
a pituitary adenoma (Fig. 2A).  Intensities of wild-type sequence peaks were weaker 
than those of mutated allele in the tumor sample, suggesting that these sequence peaks 
might be derived from the normal allele of slightly contaminated normal tissue and the 
other allele might be lost at the germline level.  To demonstrate the deletion at 17q24, 
DNA copy number of the PRKAR1A gene was measured by qPCR using 5 primer sets 
as shown in Fig. 2B (upper diagram).  The DNA copy numbers of the PRKAR1A gene 
were reduced by almost half in leukocyte genomic DNA from the proband (III-2) and 
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her mother (II-2), compared with that from the father (II-1) (Fig. 2B), suggesting the 
inherited deletion of the PRKAR1A gene in the family. 
 
Identification of the breakpoints on 17q24 
   To identify the range of deletion at 17q24 in the leukocyte genomic DNA, we 
measured DNA copy number at each locus in the vicinity of the PRKAR1A gene (Fig. 
3A) and found that the deletion is in the vicinity of the LOC732538 gene to intron 1 in 
the FAM20A gene (data not shown).  We designed sets of 4 primers in intron 1 of the 
FAM20A gene and in the vicinity of the LOC732538 gene (P1-P4 and p1-p4 in Fig. 3B 
and 3C) to detect DNA copy number in the loci.  The qPCR analyses narrowed the 
breakpoints to a 1.3 kb region between P2 and P3 in intron 1 of the FAM20A gene (Fig. 
3B) and to 14 kb between p2 and p3 surrounding the LOC732538 gene (Fig. 3C). 
   To identify the breakpoints, cloning of a region encompassing the deletion junction 
was attempted (supplementary Figs. 1A-1C).  The cloned DNA contained sequences of 
intron 1 of the FAM20A gene and the LOC732538 gene, and a 24 bp region in which 
they overlapped (supplementary Figs. 1D and 1E), suggesting that each breakpoint 
 12 
should be located in the overlapping region and the deletion size in genomic DNA was 
approximately 0.5 Mb.  The deletion size and the location were consistent with results 
obtained from comparative genomic hybridization (CGH) array analysis (supplementary 
Fig. 2).  Finally, we designed a primer set to detect the deletion and confirmed that the 
family members (II-2, III-1, III-2), except for the proband’s father (II-1), had the 
germline deletion by the presence of 325 bp PCR products (Fig. 3D).  Her 
grandmother’s leukocytes were unavailable.  
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Discussion 
   The most common type of endocrine tumor in CNC is PPNAD, which was detected 
in 25-30% of the patients (2).  In this family, her mother developed bilateral adrenal 
tumors, while pathological findings of right resected tumors were unavailable.  
Although almost all CNC patients (75%) exhibit asymptomatic elevations in serum GH, 
IGF-1, or PRL level, acromegaly with pituitary adenomas occurs in a smaller 
population of the patients (approximately 10%) (9).  Gigantism is frequent in CNC; in 
addition to two adolescents with gigantism published in individual cases reports (10, 
11), several large series of patients with CNC and GH-secreting pituitary tumors have 
been published which have included cases with gigantism (5). 
   To our knowledge, this is the first proven CNC-related pituitary adenoma with the 
combination of a large inherited deletion on 17q24 and a somatic frameshift PRKAR1A 
mutation.  This study suggests that the standard sequencing method alone is 
insufficient to detect the genetic abnormalities in leukocytes and tumors.  In this study, 
we estimated the existence of a deletion at the germline level in the family because of 
the weaker sequencing peaks of the normal allele in addition to somatic frameshift 
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mutation in the tumor (Fig. 2A).  However, if the tumor had a large biallelic deletion, 
we might misdiagnose it as normal due to the sequencing peak derived from 
contaminated normal tissue.  Therefore, even if no mutations were detected in both 
leukocytes and tumors by sequencing analysis, measurement of DNA copy number at 
the locus of tumor suppressor gene may be necessary.  Because of the expense of CGH 
array and the commercial unavailability of multiplex ligation-dependent probe 
amplification for the PRKAR1A gene, qPCR of genomic DNA may be the first-line 
method for detecting a large deletion. 
   In approximately 75% of CNC patients, germline mutations in the PRKAR1A gene 
have been reported (12).  Large deletions of the gene loci at 17q24.2-24.3 have 
recently been detected in 7.7% (13) and 21.6% (7) of PRKAR1A mutation-negative 
patients with CNC.  The mutations and large deletions leading to PRKAR1A 
haploinsufficiency have been considered to cause CNC.  However, whether 
haploinsufficiency of PRKAR1A is sufficient for the development of pituitary adenomas 
in CNC remains unknown.  Because of the low frequency of pituitary adenomas, 
reports on biallelic inactivation of PRKAR1A in CNC-related pituitary tumors have been 
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scarce.  In the first report about inactivating mutations of the PRKAR1A gene in CNC, 
one of two GH-producing pituitary adenomas showed germline mutation and somatic 
loss of heterozygosity (LOH), while another adenoma was uninformative (12).  Bossis 
et al. (14) and Takano et al. (15) reported LOH in pituitary adenomas with 
PRKAR1A-inactivating germline mutation.  On the other hand, CGH revealed that loss 
of 17q was not observed in 4 pituitary adenomas from patients with CNC (16); however, 
this method may be inadequate to identify whether these tumors have inactivating 
mutations or a small deletion.  In this study, we demonstrated that biallelic inactivation 
of PRKAR1A gene in a CNC-related pituitary adenoma and loss of the protein 
expression in the tumor cells (Fig. 1D). 
   Studies in mouse models have provided evidence that the development of a 
CNC-related pituitary tumor requires tumor-specific loss of the normal allele of the 
Prkar1a gene.  Although Prkar1a knockout (KO) mice show embryonic lethality (17, 
18), heterozygous Prkar1a KO mice develop sarcomas, hepatocellular carcinomas, and 
tumors in highly CNC-relevant tissue such as Schwann cells, osteoblasts, and 
thyrocytes, but not pituitary adenomas (18, 19).  In contrast, pituitary-specific Prkar1a 
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KO mice develop pituitary tumors at a significantly higher frequency than that observed 
in control littermates (20). 
   In conclusion, we found somatic inactivating mutation in GH-producing adenoma in 
a family with a large inherited deletion of the PRKAR1A locus.  This suggests that the 
complete loss of PRKAR1A might be necessary for the development of at least some 
pituitary adenomas in CNC.  
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Figure legends 
Figure 1.  (A) Preoperative coronal T1-weighted enhanced MRI of the proband and 
histopathology of pituitary tumor.  MRI demonstrates a pituitary tumor (15 mm in 
diameter) located in the left wing.  (B-D) Hematoxylin and eosin staining (B) and 
immunostaining using antibodies against GH (C) and type 1α regulatory subunit of 
PKA (D) in serial sections of pituitary adenoma with adjacent normal pituitary cells 
(left upper side).  (E) A pedigree of the CNC family and histological findings of 
tumors.  The proband is indicated by an arrow.  Family members are indicated by 
generation (Roman numerals) and individuals (Arabic numerals).  Individuals are 
represented as male (squares) and female (circles).  Filled symbols denote patients 
with CNC. 
 
Figure 2.  Mutation and deletion analyses of the PRKAR1A gene in a CNC family.  
(A) Scanned segments of sequencing electropherograms of leukocytes (left) and the 
tumor (right) DNA from the proband.  At the top of each panel, nucleotide sequences 
of wild type (black) and a frameshift mutation (red) are indicated.  (B) Validation of 
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PRKAR1A deletion by qPCR.  Upper diagram shows the genomic structure of the 
PRKAR1A gene.  The vertical lines indicate positions where DNA copy numbers were 
measured in introns (Int) 1, 3, 5, and 8 and exon (ex) 11.  The graph shows relative 
DNA copy numbers at each indicated region of the PRKR1A gene compared with the 
TBP gene in leukocytes from the proband (III-2, P), father (II-1, F), and mother (II-2, 
M) and the tumor (T).  The albumin (ALB) gene on 4q13.3 was analyzed as a control.    
 
Figure 3.  Deletion analyses at several loci on 17q24.  (A) Schematic diagram of the 
17q24 region.  Arrows indicate the orientation of genes in the 5’ to 3’ direction.  (B) 
Relative DNA copy number at positions in intron 1 of FAM20A downstream of the 
PRKAR1A gene compared with the TBP gene.  Using the set of 4 primers (P1-P4) 
indicated in the upper diagram, relative DNA copy number at 4 positions in intron 1 of 
FAM20A was measured by qPCR in leukocytes from the proband (III-2, P), father (II-1, 
F), and mother (II-2, M) and in the tumor (T).  (C) Relative DNA copy number at loci 
in the vicinity of the LOC732538 gene compared with the TBP gene.  Using the set of 
4 primers (p1-p4) in each position, relative DNA copy number was measured in the 
 26 
same way.  (D) Identification of the large deletion on 17q24 in family members.  
Estimated size of PCR products amplified from a wild-type allele and an allele with the 
deletion using a primer set (arrow) to detect the deletion (upper diagram).  
Representative electropherogram of PCR products for leukocytes DNA from the 
proband (III-2, P), her father (II-1, F), mother (II-2, M), and sister (III-1, S).  PCR 
using a primer set for the TERT gene on 5p15.33 as an internal control was also 
performed.  NC, no template control.  C, control genomic DNA.  PC, a plasmid 
including DNA encompassing a deletion junction. 
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Supplementary data 
 
Methods 
Cloning of DNA fragments encompassing a deletion junction 
   DNA encompassing a deletion junction on 17q24 was amplified by using 
leukocyte-derived genomic DNA from the proband and KOD FX DNA polymerase 
(Toyobo) with the following primers: forward: 5´-GCTGAGCTCCAGTGATCTCC-3´, 
reverse: 5´-CTCACCCACACGTTCCTTTT-3´.  PCR products were subcloned into 
pCR4-Blunt plasmid vector (Invitrogen).  Then, the approximately 1.3 kb fragment 
obtained by digestion of the plasmid with HindIII and EcoRI was subcloned into 
pBluescript II SK+ followed by sequencing analysis. 
 
PCR conditions 
   PCR condition for gene mutation analysis: 94˚C for 5 min; followed by 35 cycles of 
94˚C for 45 sec, 62˚C (for the exon 9 primer set) or 57˚C (for the others) for 30 sec; 
72˚C for 30 sec; and then 72˚C for 5 min.  For cloning of DNA fragments 
encompassing a deletion junction: 94˚C for 2 min; followed by 35 cycles of 98˚C for 10 
 2 
sec, 60˚C for 30 sec, 68˚C for 7 min; and then 68˚C for 5 min.  For detection of deleted 
allele: 94˚C for 5 min; followed by 37 cycles of 94˚C for 30 sec, 66˚C for 30 sec, 72˚C 
for 30 sec; and then 72˚C for 5 min. 
 
CGH array analysis 
   CGH array analysis of genomic DNA from the tumor sample was performed using 
Affymetrix CytoScan HD arrays (Affymetrix, Santa Clara, CA, USA), according to the 
manufacturer’s recommended protocol.  Images were acquired using the GeneChip 
Scanner 3000 7G (Affymetrix) and analyzed using Chromosome Analysis Suite v2.1 
software (Affymetrix).  This analysis was supported by the Support Center for 
Advanced Medical Sciences, Institute of Health Biosciences, the University of 
Tokushima Graduate School. 
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Figure legends 
 
Supplementary Figure 1 
Identification of breakpoints on 17q24 in the CNC family.  (A) Schematic diagrams of 
deleted allele (her mother, II-2, and the proband, III-2) and wild-type allele (her father, 
II-1) in the family.  To amplify the genomic DNA fragment including a deletion 
junction, a forward primer of p2 shown in Fig. 3C and a reverse primer of P4 shown in 
Fig. 3B were used.   The size of the fragment amplified by PCR was expected to be 
between 1.7 kb and 17 kb.  (B) A representative image of PCR products on agarose gel 
electrophoresis.  Approximately 8.7 kb fragments were amplified in leukocytes DNA 
from the proband (III-2, P) and her mother (II-2, M), but not her father (II-1, F).  (C) 
Restriction enzyme mapping of the PCR fragment of approximately 8.7 kb.  Solid and 
dashed vertical lines indicate EcoRI and HindIII recognition sites, respectively.  The 
deletion junction was predicted to be contained in a 1.3 kb fragment digested with 
EcoRI and HindIII.  (D) A scanned segment of a sequencing electropherogram of the 
PCR product encompassing the deletion junction.  At the top of the panel, nucleotide 
 4 
sequences derived from LOC732538 (blue) and FAM20A (red) and the overlapping 
sequences (purple) are shown.  (E) Alignment of sequences of LOC732538 (upper: the 
position from 68098595 to 68098977 on chromosome 17) and FAM20A (lower: the 
position from 68594167 to 68594547 on chromosome 17).  Red color indicates 
sequences of the PCR products encompassing the deletion junction.  Positions of PCR 
primers used to identify the deletion are underlined.  A box denotes the 24 bp region of 
overlap between the FAM20A gene and the LOC732538 gene in the PCR product.   
 
Supplementary Figure 2 
Identification of a large deletion at 17q24 by CGH array analysis.  A deletion was 
detected on chromosome 17q24.  Each dot represents weighted log2 ratio of each 
marker in the vicinity of the deleted region.  The deletion was estimated to be 
approximately 0.5 Mb between LOC732538 and intron 1 of the FAM20A. 
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Supplementary Table.  Sequences of primers used for qPCR 
 
Gene (location)  Sequence 
TBP F 5´-CTGTTTCTTGGCGTGTGAAG-3´ 
(chr.6: 170556927-170557029) R 5´-CGCTGGAACTCGTCTCACTA-3´ 
ALB F 5´-TGAAACATACGTTCCCAAAGAGTTT-3´ 
(chr.4: 73418213-73418293) R 5´-AGCAGGTTGCTTGAAATGCT-3´ 
TERT F 5´-CTCTCCTTCTCAGAAAGTGTGCATAT-3´ 
(chr.5: 1291864-1292015) R 5´-AAGGAAGCTGGAGCACAAAA-3´ 
PRKAR1A Intron 1 F 5´-GTTGACTTTTGTGCCCTGGT-3´ 
(chr.17: 68514986-68515151) R 5´-TCAGCTCCTGGGAGGAAGTA-3´ 
PRKAR1A Intron 3 F 5´-GACCCACTTGGTGGTCATCT-3´ 
(chr.17: 68522965-68523172) R 5´-CTGCAAAACAACTGCAAGGA-3´ 
PRKAR1A Intron 5 F 5´-ATTTTGTGGCAGCCTGATA-3´ 
(chr.17: 68524581-68524781) R 5´-GGGGAAAGAAAATCAAGCAA-3´ 
PRKAR1A exon 8/Intron 8 F 5´-GGGAAGCACACTGAGAAAGC-3´ 
(chr.17: 68527839-68528081) R 5´-AGACGGGAAGTCACAGAGGA-3´ 
PRKAR1A exon 11 F 5´-GGGCATGAGATTTTGGAAGA-3´ 
(chr.17: 68531519-68531674) R 5´-AAGCAGGACTTTCAGCAGGA-3´ 
FAM20A Intron 1 primer set-1 (P1) F 5´-ACCACCCTGCTGAGACATTC-3´ 
(chr.17: 68593312-68593551) R 5´-CAGAGCAGGGATAGCTTTGG-3´ 
FAM20A Intron 1 primer set-2 (P2) F 5´-CCTTCCCAAAGGAGGAAAAG-3´ 
(chr.17: 68593928-68594174) R 5´-CTCCCAAAGTGCTGGGATTA-3´ 
FAM20A Intron 1 primer set-3 (P3) F 5´-GCAGGAAGTGCCTGTCTTTC-3´ 
(chr.17: 68595265-68595458) R 5´-GGAGGAAACCTCTCCACTCC-3´ 
FAM20A Intron 1 primer set-4 (P4) F 5´-GGTTTGCAGAAAGCTTCAGG-3´ 
(chr.17: 68596910-68597107) R 5´-CTCACCCACACGTTCCTTTT-3´ 
LOC732538 primer set-1 (p1) F 5´-GGTGTGCTGGGGTAATGAAC-3´ 
(chr.17: 68085662-68085849) R 5´-CAGCCCAGTGGCTGAATAC-3´ 
LOC732538 primer set-2 (p2) F 5´-GCTGAGCTCCAGTGATCTCC-3´ 
(chr.17: 68092953-68092953) R 5´-AGCTGGATGTGGTAGCAGGT-3´ 
LOC732538 primer set-3 (p3) F 5´-GAGGATCTCATTAGGGCCTGT-3´ 
(chr.17: 68106871-68107022) R 5´-GCGTATTTCAAGGGTTCAGC-3´ 
LOC732538 primer set-4 (p4) F 5´-AATCTTAAGTTTGATTGGCAGTTTG-3´ 
(chr.17: 68110265-68110414) R 5´-GGAGGTTGTGGTGAGCAGAG-3´ 
  
68098595 TTTGGGAGGCCAAGCCGGGCGGATCATGAGGTCAGGAGATTGGGACCATCCTGGCTAACACGATGAAAC-CCTGTCTCTACTAAAAATACAAAAAATTAG 68098693
         ||||||||||| || ||||||||||| ||||||||||||| | |||||   |||         |||||| || |||||||||||||||||||||| ||||
68594167 TTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGACCA---TGG---------TGAAACGCC-GTCTCTACTAAAAATACAAAAAGTTAG 68594253
68098694 CCAGGCGTGGTGCCGGGCGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATGGTGTGAACCCGGCAGGTGGAGCTTGTAGTGAGCCGAGATG 68098793
         |  ||||| ||| |||||||||||||||||||||||| ||||||||||||||||||||||| |||||||||| ||| |||||||| ||||||||||||| 
68594254 CTGGGCGTAGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCCGAGATC 68594353
68098794 GCGCCACTGCACTCCAGCCTGGGCGACGGAACGAGACTCCGTCTCAAAAAAAAA---TCCCC-CACGCTG----TTGTCCTTACTAGTTTACTTTGTGCT 68098885
         ||||||||||||||||||||||||||| || |||||||||||||||||||||||    |    ||   |     ||||| || ||| ||  || | |   
68594354 GCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAACAAAACAGTATTGTATTTGTC-TT-CTA-TTG-CTGTATAAC 68594449
68098886 AGACACTTTTGCATGTA-TATGCATACAACTTTTATTCTGTTTTTAAAC-----TTTGCATTACATATACATT-CTTCCATATTATATGAT-CTTCATTA 68098977
         |||         |  || ||    || |||           ||           |||| |   || ||       ||        | | || |||    
68594450 AGAGTACCACAAACCTAGTAACT-TAAAACAACACTCATTAATTAGCTCACAGTTTTGTAGGTCAGATGTCCAGCTTGGTGTGGCTGT-ATGCTTTGCAC 68594547
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